In addition, a Phase II study of alisertib in breast, head and neck, gastro-esophageal, small-cell and non-small-cell lung cancer demonstrated modest single agent activity, with hormone receptor and HER-2 positive breast cancer patients giving the best objective response [20]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.